Chemo infusion after liver cancer surgery to lower recurrence risk
Part of Cancer, Digestive system clinical trials.
This trial tests whether a targeted chemotherapy infusion directly into the liver's main artery (HAIC) after surgery can prevent liver cancer from coming back. It is for people with certain high-risk features, like a large tumor or cancer in blood vessels, who have had their tumor completely removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have had surgery to completely remove your liver cancer within the last 8 weeks, and the doctor confirmed no cancer cells were left at the edges.
- You must have one or more 'high-risk' features: a tumor larger than 5 cm, cancer cells in blood vessels, 3 or more tumors, a high-grade tumor, or a narrow surgical margin.
- Your liver and kidney function must be good enough, based on blood tests (e.g., your platelet count must be at least 80, hemoglobin at least 90).
- If you have hepatitis B or C, you must be on antiviral treatment.
- You cannot be pregnant, and you must not have active infections or serious medical conditions that would make the trial unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving chemotherapy directly into the liver artery (HAIC) combined with immunotherapy before surgery for liver cancer that can be removed but is too large or numerous for standard treatment. The goal is to shrink the tumor and improve surgery results.
This study tests a treatment given before surgery for liver cancer that is at high risk of coming back. You would receive a combination of chemotherapy directly into the liver artery (HAIC), a targeted pill (lenvatinib), and an immunotherapy drug (a PD-1 inhibitor) — if a computer model predicts you might benefit.
This trial tests a combination of liver-directed chemotherapy (HAIC), a targeted drug (lenvatinib), and an immunotherapy (envafolimab) to see if it can shrink liver cancers that are difficult to operate on. The goal is to make these cancers removable by surgery.
This trial tests whether giving chemotherapy, immunotherapy, and targeted drugs before surgery helps prevent liver cancer from coming back in patients with high-risk tumors. You would receive treatment to shrink the tumor before your scheduled surgery.
This trial tests a combination of two drugs (Donafenib and Envafolimab) after surgery to lower the risk of liver cancer coming back in people who have high-risk features. It may help if you qualify based on your tumor(s) and overall health.
This trial tests whether a combination of two therapies—targeted chemotherapy delivered directly to the liver (TACE) plus immunotherapy (atezolizumab) and a targeted drug (bevacizumab)—can keep liver cancer from coming back after surgery. It is for people whose tumors can be surgically removed but are at high risk of recurrence.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.